NCT03007303|UnknownDMC
Loading search results
Sponsor study identifier
observational
30
1 country
1
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
November 17, 2016
Actual (reported)January 2, 2017
Actual (reported)March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
the Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection
before the treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection
Change from Baseline expression level at 4-week treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 8-week treatment for the microRNA-30e detection
Change from Baseline expression level at 8-week treatment
the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia
before, after 4 weeks and 8 weeks treatment
The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia
before, after 4 weeks and 8 weeks treatment
The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment
4 weeks and 8 weeks treatment
15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT. The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated.
15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
the first-onset schizophrenia patients or drug-free suffers in the last 3 months，who are Chinese of Han descent and admitted to the Dalian Seventh People's Hospital,China
Dalian Seventh People's Hospital
Dalian, Liaoning, 116023, China
Xu C, Liu X, Song X, Gao Q, Cheng L, Wang L, Zhang K, Xu Y. Aberrant resting state in microRNA-30e rat model of cognitive impairment. Neuroreport. 2016 Aug 3;27(11):809-17. doi: 10.1097/WNR.0000000000000616.
Xu Y, Li F, Zhang B, Zhang K, Zhang F, Huang X, Sun N, Ren Y, Sui M, Liu P. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr Res. 2010 Jun;119(1-3):219-27. doi: 10.1016/j.schres.2010.02.1070. Epub 2010 Mar 27.
The peripheral blood sample Plasma separated from the peripheral blood
Shoufu Xie, postgraduate
Dalian Seventh People's Hospital
First Submitted
November 17, 2016
First Posted
January 2, 2017
Study Start
June 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J, Costa J, Schmitt A, Schneider A, Cabral H, Cagsal-Getkin O, Vanderburg CR, Delalle I. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One. 2013;8(1):e48814. doi: 10.1371/journal.pone.0048814. Epub 2013 Jan 30.
March 2020
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 30, 2020
Record last verified: 2020-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: